Introduction:

Nirmatrelvir/ritonavir (Paxlovid®) is the only oral treatment authorized in Europe to treat COVID-19 disease in adults who do not require supplemental oxygen and who are at high risk for progression to severe COVID-19.

It is available in Spain after validation due to the profile of interactions and warnings for use.

The objective is to determine effectiveness, safety and management of interactions.

Method:

Retrospective study of all patients on validated nirmatrelvir/ritonavir treatment at three urban health centres during 2022. Effectiveness was the proportion of participants without COVID-19-related hospitalization or death from any cause through day 28.

Results:

24 patients were analyzed. It was considered effective in 23 (95.8 %). More than 80 % of patients presented potential interaction with the concomitant medication, recommending the temporary suspension of medications, highlighting simvastatin and metamizole.

Conclusions:

Nirmatrelvir/ritonavir has been considered effective but difficult to manage in polymedicated polypathological patients.

        · |     · |     · ( pdf )